🔍

Syngene International Limited (SYNGENE)

₹386.10 +0.49% last close, 16 Oct

📊 NSE: SYNGENE 🏢 Healthcare Research, Analytics & Technology 📢 Latest filing: 08 Oct 2026 📝 Analysis written: 14 Dec 2025

Q2 FY27 results

📅 Next results: 27 Oct 2026 (board meeting)

Syngene International Limited's board meets on 27 Oct 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Syngene International's revenue was ₹736 Cr (-15.8% year on year, -29.0% on the previous quarter), and net profit ₹-9.0 Cr (against a profit a year earlier); the operating margin was 12.3%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹736	-15.8%	-29.0%
Operating profit	₹90.8	-56.0%	-70.0%
Net profit	₹-9.0	to loss	to loss
EPS (₹)	-0.22	to loss	to loss
Operating margin	12.3%	—	—

Full quarterly financials → Results calendar →

SYNGENE delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 49.16% of the SYNGENE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 52.75%. That is close to its usual level. Volume was 0.5 times its average, well below normal.

49.16%Delivery, 16 Oct

52.75%Own 20-session average

0.5×Volume vs its average

₹386.10NSE close · +0.49%

Delivery in the last 5 sessions: 22.3% · 40.7% · 52.2% · 51.1% · 49.2%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Syngene Submits Regulation 74(5) Dematerialisation Certificate for Q2 FY27

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 08 Oct 2026, 06:55 PM

Syngene International Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar and Transfer Agent (RTA) KFin Technologies Limited, covers the quarter ended September 30, 2026. KFin confirmed that all dematerialisation requests received between July 1, 2026, and September 30, 2026, were processed within the mandated 15-day timeline. This filing represents standard regulatory housekeeping and carries no operational or financial impact.

Regulation 74(5) dematerialisation compliance confirmed for the period July 1, 2026, to September 30, 2026
RTA KFin Technologies verified processing of demat requests within 15 days of receipt
RTA confirmation letter dated October 6, 2026, submitted to exchanges on October 8, 2026

💡 No investor action is required. Investors should track upcoming Q2 financial results and operational updates for material business performance cues.

Syngene to Attend Kotak Healthcare Forum 2026 on September 17

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Sep 2026, 08:22 PM

Syngene International Limited has informed the exchanges regarding its scheduled participation in an investor conference. The company will participate in the Healthcare Forum 2026 organized by Kotak on September 17, 2026, in Mumbai starting at 09:00 AM IST. The interactions will involve physical group and one-on-one meetings. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Scheduled meeting date: September 17, 2026
Organized by Kotak (Healthcare Forum 2026)
Format: Physical Group / One-on-one Meeting starting at 09:00 AM IST
Meeting venue: Mumbai
Company affirmed zero Unpublished Price Sensitive Information (UPSI) will be disclosed

💡 Track if any investor presentation or transcript is uploaded following the conference, and watch for Q2 FY27 operational commentary.

Syngene Schedules One-on-One Analyst Meet with True Beacon PMS for Sept 17, 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 11 Sep 2026, 07:12 PM

Syngene International Limited has notified exchanges regarding a scheduled one-on-one virtual meeting with True Beacon PMS. The interaction is set to take place on September 17, 2026, at 12:00 PM IST. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the call. This is a routine institutional investor interaction filing under Regulation 30(6) of SEBI LODR.

One-on-one virtual meeting scheduled with True Beacon PMS
Meeting date set for September 17, 2026
Meeting time scheduled at 12:00 PM IST
Company confirmed no Unpublished Price Sensitive Information (UPSI) will be disclosed

💡 Track subsequent post-meet disclosures or presentations on the exchange if uploaded, though no new material data is expected.

Syngene Remits FY26 Final Dividend of Rs 1.25 Per Share (12.5%)

🟡 NEUTRAL ⭐ 3/10

DIVIDEND 📅 10 Sep 2026, 05:18 PM

Syngene International has dispatched communications regarding the remittance of its FY 2025-26 final dividend of Rs 1.25 per equity share (12.5% on face value of Rs 10). The dividend was approved by shareholders at the AGM on July 29, 2026, with the record date set on June 26, 2026. The communication is directed at physical shareholders or those whose email addresses are not registered. Based on total shares outstanding (~40.2 crore), the total dividend payout is approximately Rs 50.3 crore, representing about 15.8% of FY26 net profit (Rs 317.4 crore).

Final dividend rate of 12.50% amounting to Rs 1.25 per equity share of face value Rs 10
Shareholder approval granted at the AGM on July 29, 2026
Record date for dividend entitlement was Friday, June 26, 2026
Remittance communication dispatched on September 10, 2026 to shareholders without registered emails

💡 Shareholders awaiting dividend credits should verify their registered bank accounts and contact the RTA (KFin Technologies) if credit is not received.

Syngene Grants 14.26 Lakh Performance Share Units Under Long Term Incentive Plan

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Sep 2026, 11:24 PM

Syngene International has granted 14,26,061 Performance Share Units (PSUs) to eligible employees on September 1, 2026, under its PSP 2023 plan. Each PSU entitles the holder to one equity share at an exercise price of Rs. 10 per share. The units follow a 3-year cliff vesting schedule (0:0:100), with an exercise period of 5 years post-vesting. The total grant represents approximately 0.35% of total outstanding equity shares, indicating minimal dilution.

14,26,061 Performance Share Units (PSUs) granted on September 1, 2026
Exercise price fixed at Rs. 10 per PSU
100% cliff vesting after a 3-year performance period (0:0:100)
Exercise window of 5 years from the date of vesting

💡 Track subsequent quarterly employee benefit expenses and ESOP cost amortization in the upcoming Q2 FY27 results.

Syngene to Attend Goldman Sachs Asia Leaders Conference on Aug 31 – Sep 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Aug 2026, 04:28 PM

Syngene International has scheduled participation in the Goldman Sachs Asia Leaders Conference 2026 from August 31, 2026, to September 1, 2026. The meetings will be conducted in person via group and one-on-one sessions in Hong Kong. The company affirmed that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Conference schedule: August 31, 2026 to September 1, 2026
Event: Goldman Sachs Asia Leaders Conference 2026 in Hong Kong
Format: In-person group and one-on-one meetings
Compliance: Company confirmed no UPSI will be disclosed

💡 This is a routine regulatory intimation; track the company website or exchange filings for any investor presentation materials published around the event.

Syngene to Acquire up to 12.44% Stake in Ampin C&I Power Twelve for ₹2.52 Cr

🟡 NEUTRAL ⭐ 3/10

M&A 📅 24 Aug 2026, 05:58 PM

Syngene International has entered into a share subscription and power purchase agreement to acquire a 12.44% stake (undiluted) in Ampin C&I Power Twelve Private Limited for ₹2.52 crore. The investment is structured to meet captive power procurement rules under the Electricity Act, helping the company procure green power and lower energy costs. Post future dilution from other incoming investors, Syngene will maintain a minimum 7.93% fully diluted equity stake. The ₹2.52 crore outlay represents less than 0.1% of Syngene's annual revenue and is immaterial to its financial position.

Investment of ₹2.52 crore for 25,20,000 equity shares at ₹10 each
Acquiring 12.44% initial undiluted stake, with a minimum 7.93% on a fully diluted basis
Target is a renewable energy generation SPV with Nil revenue and ₹0.31 lakh PAT in FY26
Allotment expected to be completed within 30 days

💡 No action required. This is a routine operational filing for captive renewable energy compliance.

Syngene Schedules One-on-One Investor Meeting on August 28, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Aug 2026, 02:41 PM

Syngene International Limited has informed the exchanges about a virtual one-on-one meeting scheduled with Entrust Family Office on August 28, 2026, at 12:00 PM IST. The interaction is a routine investor relations update conducted under SEBI LODR Regulation 30(6). The company clarified that no Unpublished Price Sensitive Information (UPSI) will be shared during this meeting.

One-on-one virtual meeting scheduled with Entrust Family Office.
Meeting date and time: August 28, 2026, at 12:00 PM IST.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.

💡 Track if any new presentation or transcript is uploaded to the exchange following the meeting; no immediate operational or trading action is required.

Syngene to Participate in Emkay Confluence 2026 Conference on August 13-14

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Aug 2026, 05:10 PM

Syngene International has scheduled in-person meetings with analysts and institutional investors on August 13 and 14, 2026. The meetings will be held at the Emkay Confluence 2026 conference in Mumbai and will include both group and one-on-one formats. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during these sessions. This is a routine investor relations activity following the company's FY26 performance where TTM revenue stood at Rs 3,575 Cr.

Meetings scheduled for two days: August 13, 2026, and August 14, 2026.
Participation in the Emkay Confluence 2026 conference organized by Emkay Global.
Format includes both Group and One-on-one in-person meetings in Mumbai.
Company confirms 0% disclosure of Unpublished Price Sensitive Information (UPSI).
Engagement follows a period where TTM PAT was Rs 317 Cr with a P/E of 51.6.

💡 Monitor the company's website for any post-conference investor presentations that may provide updates on the Baltimore facility operationalization (targeted for Dec 2025) and the 'China switcher' strategy.

Syngene International releases Q1 FY2027 earnings conference call transcript

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Aug 2026, 06:41 PM

Syngene International has released the official transcript for its Q1 FY2027 earnings conference call held on July 30, 2026. The company currently reports a TTM revenue of ₹3,575 Cr and a PAT of ₹317 Cr, reflecting a challenging period with a 40.5% stock price decline over the past 12 months. The transcript provides management's detailed perspective on the '1-3-5' growth plan and the operationalization of the Baltimore facility. This filing is a standard regulatory requirement to ensure transparency for all shareholders.

Earnings conference call for Q1 FY2027 was held on July 30, 2026
Official transcript published and linked on the company website as of August 06, 2026
Company reports TTM revenue of ₹3,575 Cr with an operating profit margin of 24.4%
Promoter holding remains steady at 52.68% as per March 2026 records

💡 Investors should review the transcript for specific updates on the Baltimore facility's operational timeline (targeted for Dec 2025) and management's strategy regarding 'China switchers' in the CDMO space.

Syngene Shareholders Approve Rs 1.25 Dividend and Re-appointment of MD & CEO

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 31 Jul 2026, 02:18 PM

Syngene International Limited has concluded its 33rd Annual General Meeting (AGM), with shareholders approving all nine resolutions. Key approvals include a final dividend of Rs 1.25 per equity share for FY26 and the re-appointment of Siddharth Mittal as Managing Director and CEO. While all resolutions passed, there was notable institutional scrutiny, with 23.75% of votes cast against the appointment of Dr. Arun Chandavarkar as an Independent Director and 10.01% against the special resolution for director remuneration in case of inadequate profits.

Final dividend of Rs 1.25 per equity share approved for the financial year ended March 31, 2026.
Siddharth Mittal re-appointed as Managing Director and CEO with 99.41% of votes in favour.
Special resolution for director remuneration during inadequate profits passed with 89.99% approval (10.01% against).
Appointment of Dr. Arun Chandavarkar as Independent Director saw 23.75% of votes cast against the resolution.
Total of 146,773 shareholders were on record as of the July 22, 2026 record date.

💡 Investors should monitor the operationalization of the Baltimore facility by December 2025, which is a key pillar of the company's '1-3-5' growth plan under the re-appointed leadership.

Syngene Releases Q1 FY27 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Jul 2026, 05:52 PM

Syngene International has released the audio recording of its Q1 FY27 earnings call held on July 30, 2026. This follows a fiscal year (FY26) where the company reported a revenue of 3,575 Cr and a PAT of 317 Cr. The recording provides management's perspective on current performance and the progress of strategic initiatives like the Baltimore facility. This is a standard regulatory filing to ensure transparency for all shareholders.

Earnings call for Q1 FY27 conducted on July 30, 2026
Audio recording link made available on the company website on the same day
Company maintains a TTM revenue base of 3,575 Cr
Management commentary likely covers the '1-3-5 plan' and the Baltimore facility timeline

💡 Investors should review the recording for updates on the operationalization of the Baltimore facility (targeted for Dec 2025) and management's outlook on the 'China switcher' strategy.

Syngene Q1 FY27: Revenue down 16% to ₹736 Cr; PAT drops to ₹1 Cr on lower client offtake

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 29 Jul 2026, 09:15 PM

Syngene reported a weak Q1 FY27 with revenue declining 16% YoY to ₹736 Cr, primarily due to reduced demand from a major Large Molecule CDMO client. Operating EBITDA margins halved to 12.3% from 23.6% a year ago, further pressured by a ₹50 Cr forex hedge loss. Consequently, PAT (before exceptional items) plummeted 99% to just ₹1 Cr. Management expects a recovery in H2 FY27, guiding for single-digit revenue degrowth and mid-20s EBITDA margins for the full year.

Revenue from operations fell 16% YoY to ₹736 Cr for the quarter ended June 30, 2026
Operating EBITDA margin contracted sharply to 12.3% from 23.6% in the previous year
PAT (before exceptional items) stood at ₹1 Cr, a 99% decline from ₹87 Cr in Q1 FY26
Foreign exchange hedge loss increased significantly to ₹50 Cr compared to ₹5 Cr in the same quarter last year
Management transition completed with Siddharth Mittal assuming the MD & CEO role on July 1, 2026

💡 Monitor the recovery in Large Molecule CDMO offtake and the operationalization of the Baltimore facility by Dec 2025. Investors should watch if the company can achieve its guided mid-20s EBITDA margins in H2 FY27 to offset the weak start.

Syngene 33rd AGM: Shareholders Approve Rs 1.25 Dividend and New Statutory Auditors

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 29 Jul 2026, 08:57 PM

Syngene International Limited concluded its 33rd Annual General Meeting on July 29, 2026, where shareholders considered nine key resolutions. Major outcomes include the approval of a final dividend of Rs 1.25 per equity share for FY26 and the appointment of S.R. Batliboi & Associates LLP as the new Statutory Auditors, replacing B S R & Co. LLP. The meeting also formalized the reappointment of Siddharth Mittal as MD & CEO and the induction of two new Independent Directors. These proceedings follow a fiscal year where the company reported TTM revenue of Rs 3,575 Cr and a PAT of Rs 317 Cr.

Approved a final dividend of Rs 1.25 per equity share for the financial year ended March 31, 2026
Appointed M/S S.R. Batliboi & Associates LLP as the new Statutory Auditors, succeeding B S R & Co. LLP
Reappointed Siddharth Mittal as Managing Director and Chief Executive Officer
Inducted Dr. Vijaya Chandru and Dr. Arun Chandavarkar as new Independent Directors
A total of 117 members attended the meeting conducted via video conferencing

💡 Investors should monitor the final voting results to be published within two working days to confirm the passage of all resolutions, particularly those regarding executive remuneration and director appointments.

Resignation of Independent Director Kush Parmar effective July 29, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 29 Jul 2026, 08:01 PM

Mr. Kush Parmar has resigned as an Independent Director of Syngene International Limited, effective July 29, 2026. The resignation is attributed to his increasing professional commitments in the USA and his inability to devote sufficient time to the company while residing abroad. Consequently, he will also vacate his positions on the Risk Management Committee and the Science and Technology Committee. The director has confirmed there are no other material reasons for his departure.

Resignation effective from the close of business hours on July 29, 2026
Cessation of membership in 2 board committees: Risk Management and Science and Technology
Director holds directorships in 0 other listed entities
Syngene maintains a TTM revenue of ₹3,575 Cr and a market cap of ₹16,618 Cr
Reason cited is increasing commitments in the USA and inability to devote sufficient time

💡 Investors should monitor the appointment of a replacement to the Science and Technology Committee, which is critical for overseeing the company's technical expansion in Biologics and ADC labs.

View All SYNGENE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Research Services contributed 61% of total revenue in FY25 and remained stable, while Large Molecule Development and Manufacturing grew 22% YoY, increasing its revenue share from 21% in FY24 to 25% in FY25. Discovery Services saw slower growth due to a challenging US Biotech funding environment.

Geographic Revenue Split

98% of total revenues are derived from overseas markets, with the US market alone accounting for 61% of FY25 revenues. Other key regions include Europe and Japan.

Profitability Margins

Reported PAT margin for Q2 FY26 was 7% (INR 67 Cr), a significant decline from the previous year. FY25 PAT before exceptional items was INR 474.9 Cr, down 8% YoY from INR 518.6 Cr in FY24.

EBITDA Margin

Operating EBITDA margin for H1 FY26 stood at 23%, down from 25% in H1 FY25. FY25 EBITDA margin was 28.6% (INR 1,113.6 Cr) compared to 29.1% in FY24.

Capital Expenditure

Annual organic capex is planned at INR 500-600 Cr. Q2 FY26 capex was $10 million (approx. INR 84 Cr), with 50% allocated to research services (DMPK automation, ADC labs) and 30% to CDMO facilities in Bangalore and the US.

Credit Rating & Borrowing

ICRA reaffirmed [ICRA]AA+ (Stable) for long-term ratings and [ICRA]A1+ for short-term facilities totaling INR 1,500 Cr. Adjusted gearing is exceptionally low at 0.03 times as of March 31, 2025.

⚙️ Operational Drivers

Raw Materials

Costs of chemicals, reagents, and consumables consumed represented 26.2% of revenue in Q2 FY26, totaling INR 238.5 Cr.

Import Sources

Not explicitly disclosed by country, but the company is developing a diversified supplier network to reduce dependency on high-cost suppliers.

Capacity Expansion

Acquired a Biologics manufacturing facility in Baltimore, USA (operational by Dec 2025) and another facility (Stelis Unit 3) in Bangalore to drive Large Molecule growth.

Raw Material Costs

Raw material costs in FY25 were INR 942.5 Cr, a 1% increase YoY. The company expects full-year raw material costs to stabilize around 25% of revenue.

Manufacturing Efficiency

Focus on 'level of productivity' to match 'China switcher' expectations; utilizing AI tools for process simplification and delivery turnaround time.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Achieving growth through the '1-3-5 plan' focusing on Large Molecule CDMO, operationalizing the Baltimore facility by Dec 2025, and expanding SynVent Integrated Drug Discovery (IDD) services. The company is also targeting 'China switchers'—clients moving supply chains away from China.

Products & Services

Contract research (CRO), discovery services (DMPK, ADC labs), biologics manufacturing (Large Molecule CDMO), small molecule CDMO, and payload/linker manufacturing.

Brand Portfolio

Syngene, SynVent, SynVent IDD.

New Products/Services

New capabilities in Antibody-Drug Conjugates (ADC) labs and payload/linker manufacturing to complement existing commercial capabilities.

Market Expansion

Expanding commercial teams closer to client locations in North America, Europe, and Japan; new manufacturing presence in Baltimore, USA.

Market Share & Ranking

Not disclosed in percentage terms, but noted as a leading player in the Indian contract research space.

Strategic Alliances

Maintains dedicated research centers for major clients and strategic marketing focused on high-value key account management.

🌍 External Factors

Industry Trends

The industry is shifting toward Large Molecule/Biologics CDMO; Syngene is positioning itself by increasing Biologics revenue share to 25%.

Competitive Landscape

Faces competition from global CROs, domestic players, and captive R&D centers of large pharma companies.

Competitive Moat

Moat built on high-end scientific talent, robust compliance/safety records (EcoVadis score 74/100), and long-term integrated contracts that create high switching costs.

Macro Economic Sensitivity

Highly sensitive to US Biotech funding cycles and global pharmaceutical R&D spending trends.

Consumer Behavior

Increased preference for 'one-stop-shop' providers that can handle both discovery and commercial-scale manufacturing.

Geopolitical Risks

Exposure to US-China trade shifts (China switchers) provides an opportunity, while 61% revenue concentration in the US poses a geographic risk.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to pharma regulatory approvals and clinical trial regulations; implementing digital tracking for licenses and permits.

Environmental Compliance

Earned 'Green Certification' from My Green Lab with a score >94%; EcoVadis 2025 score rose to 74/100 (91st percentile).

Taxation Policy Impact

Tax expense increased 35% YoY to INR 153 Cr in FY25. The company adopts a litigation strategy for ongoing tax cases with expert advisors.

Legal Contingencies

Ongoing tax disputes and contractual management risks are monitored by an executive-level committee; specific INR values for pending litigations not disclosed.